Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

RELATED RESOURCES

Print Format

Change Text Size:

BRIEF-XBiotech Says FDA Approves Xbiotech's IND In Rheumatology

BY Reuters
— 8:08 AM ET 12/13/2021

Dec 13 (Reuters) - XBiotech Inc (XBIT):

* FDA APPROVES XBIOTECH'S IND IN RHEUMATOLOGY

* XBIOTECH INC (XBIT) - WILL FIRST LAUNCH NATRUNIX IN A PHASE I STUDY TO EVALUATE DOSING FOR SUBCUTANEOUS INJECTIONS

* XBIOTECH INC (XBIT) - ONCE PRELIMINARY DOSING HAS BEEN ESTABLISHED, COMPANY PLANS TO PROCEED WITH PHASE II STUDIES IN RA Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More XBIT News

FDA Approves XBiotech’s IND in Rheumatology
GlobeNewswire - 8:00 AM ET 12/13/2021